You are here

  • Home
  • Archive
  • Volume 17, Issue 4
  • Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)

Article metrics

Article menu
Download PDFPDF
Original Articles
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)

 

Online download statistics by month:

Online download statistics by month: February 2019 to October 2024

AbstractFullPdf
Feb 2019800
Mar 2019501
Apr 2019700
May 2019600
Jun 2019300
Jul 2019500
Aug 2019300
Oct 2019500
Nov 2019500
Dec 20191200
Jan 20202600
Feb 2020900
Mar 2020300
Apr 2020200
May 20201200
Jun 2020500
Jul 2020600
Aug 2020400
Sep 20201200
Oct 20201000
Nov 2020400
Dec 2020800
Jan 2021200
Feb 2021801
Mar 2021200
Apr 2021301
May 2021201
Jun 2021001
Aug 2021001
Sep 2021002
Oct 20211501
Nov 20211205
Dec 20211500
Jan 20221000
Feb 20223402
Mar 20221804
Apr 20222101
May 20223401
Jun 20224302
Jul 20221402
Aug 20223301
Sep 20223402
Oct 20225302
Nov 20221400
Dec 2022700
Jan 20231001
Feb 20235902
Mar 20231101
Apr 2023300
May 2023402
Jun 2023200
Jul 20232402
Aug 20231603
Sep 2023501
Oct 20231401
Nov 20233506
Dec 20232000
Jan 20242400
Feb 20241100
Mar 20241802
Apr 20242202
May 20241201
Jun 20242102
Jul 20241704
Aug 20241800
Sep 20242206
Oct 2024200
Total904067